ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Consensus Rating of "Moderate Buy" by Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) has received a consensus rating of "Moderate Buy" from the six analysts that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $77.33.

Several equities analysts have recently weighed in on ANIP shares. Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. HC Wainwright reiterated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler initiated coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an "overweight" rating and a $68.00 target price for the company. Finally, Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th.

ANI Pharmaceuticals Trading Up 0.2 %

ANIP traded up $0.12 during trading on Monday, hitting $57.35. The company's stock had a trading volume of 130,095 shares, compared to its average volume of 218,427. ANI Pharmaceuticals has a twelve month low of $48.20 and a twelve month high of $70.81. The firm's 50 day moving average price is $58.22 and its 200-day moving average price is $60.61. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The stock has a market cap of $1.21 billion, a PE ratio of -104.05 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business posted $1.05 earnings per share. The firm's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, analysts expect that ANI Pharmaceuticals will post 3.87 earnings per share for the current year.

Insider Buying and Selling at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of the company's stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 33,981 shares of company stock valued at $1,970,066. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ANIP. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock worth $90,314,000 after purchasing an additional 17,460 shares in the last quarter. State Street Corp boosted its stake in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. State Street Corp now owns 703,843 shares of the specialty pharmaceutical company's stock valued at $41,991,000 after buying an additional 58,698 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 3.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock valued at $40,132,000 after acquiring an additional 21,053 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of ANI Pharmaceuticals by 23,259.8% in the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after acquiring an additional 565,910 shares during the last quarter. Finally, Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after acquiring an additional 9,500 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.